主权项 |
1. A method for the therapeutic treatment of a patient who has been diagnosed with a physiological functional disorder selected from among pre-diabetes, glucose intolerance, pathological fasting glucose, diabetic foot, diabetes-associated ulcer, diabetic hyperlipidaemia, diabetic dyslipidaemia, newly diagnosed type 1 diabetes, gestational diabetes, hyperglycaemia, adrenergic postprandial syndrome and heart failure, or for the therapeutic treatment of a patient with transplanted islets of Langerhans or beta cells, the method comprising administering a DPP IV inhibitor of formula (I) or of formula (II) or one of the salts thereof, wherein R1 denotes ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl, or (4,6-dimethyl-pyrimidin-2-yl)methyl, and R2 denotes 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino; optionally in combination with an active substance selected from among the other antidiabetics; active substances that lower the blood sugar level; active substances that lower the lipid level in the blood; active substances that raise the HDL level in the blood; active substances that lower blood pressure; and active substances that are indicated in the treatment of atherosclerosis or obesity. |